177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)
A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jakob Stenman, MD PhD
- 전화번호: 46 (0)51770000
- 이메일: jakob.stenman@regionstockholm.se
연구 연락처 백업
- 이름: Kleopatra Georgantzi, MD
- 전화번호: 46 (0)51770000
- 이메일: kleopatra.georgantzi@regionstockholm.se
연구 장소
-
-
Utrecht
-
Utrecht, Utrecht, 네덜란드, NL-3584
- 모병
- Princess Maxima Center for Pediatric Oncology
-
연락하다:
- Max M van Noesel, MD PhD
- 이메일: M.M.vanNoesel@prinsesmaximacentrum.nl
-
수석 연구원:
- Max M van Noesel, MD PhD
-
-
-
-
Oslo
-
Oslo, Oslo, 노르웨이, NO-0372
- 모병
- Oslo University Hospital, Rikshospitalet
-
연락하다:
- Kirsten Brunsvig Jarvis, MD
- 이메일: kirjar@ous-hf.no
-
수석 연구원:
- Kirsten Brunsvig Jarvis, MD
-
-
-
-
Copenhagen
-
Copenhagen, Copenhagen, 덴마크, DK-2100
- 모병
- Rigshospitalet
-
연락하다:
- Jesper S Brok, MD PhD
- 이메일: jesper.sune.brok@regionh.dk
-
수석 연구원:
- Jesper S Brok, MD PhD
-
-
-
-
Vilnius County
-
Vilnius, Vilnius County, 리투아니아, LT-08406
- 모병
- Vilnius University Hospital
-
연락하다:
- Jelena Rascon, MD PhD
- 이메일: jelena.rascon@gmail.com
-
수석 연구원:
- Jelena Rascon, MD PhD
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, 스웨덴, SE-171 76
- 모병
- Karolinska University Hospital
-
수석 연구원:
- Kleopatra Georgantzi, MD
-
연락하다:
- Kleopatra Georgantzi, MD
- 이메일: kleopatra.georgantzi@regionstockholm.se
-
연락하다:
- Jakob Stenman, MD PhD
- 이메일: jakob.stenman@regionstockholm.se
-
-
-
-
-
Barcelona, 스페인
- 모병
- Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
-
연락하다:
- Maite Gorostegui Obanos, MD
- 전화번호: +34 93 280 40 00
- 이메일: maite.gorostegui@sjd.es
-
수석 연구원:
- Maite Gorostegui Obanos, MD
-
-
-
-
-
Glasgow, 영국, G51 4TF
- 모병
- GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
-
연락하다:
- Diana Mcintosh, Consultant Paediatric Oncologi
- 이메일: Diana.Mcintosh2@nhs.scot
-
수석 연구원:
- Diana Mcintosh, MD
-
London, 영국, NW1 2PG
- 모병
- University College London Hospitals NHS FOUNDATION TRUST
-
연락하다:
- Jenny Gains, Consultant in Clinical Oncolog
- 전화번호: +44-203 447 4437
- 이메일: jenny.gains@nhs.net
-
수석 연구원:
- Jenny Gains, MD
-
London, 영국, SW3 6JJ
- 모병
- The Royal Marsden NHS Foundation Trust of Fulham Road
-
연락하다:
- Sucheta Vaidya, Paediatric Oncologist
- 이메일: Sucheta.Vaidya@rmh.nhs.uk
-
수석 연구원:
- Sucheta Vaidya, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
- Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
- Age >18 months at the time of enrolment into this study
- Life expectancy of greater than 3 months
- Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
- Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
- Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
- Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
- Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
- Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures
Exclusion Criteria:
- Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
- Pregnant or lactating patient
- Concurrent treatment with any anti-tumor agents
- Prior treatment with other radiolabeled somatostatin analogues
- Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
- Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
- Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 177Lu-DOTATATE
A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks. |
A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
기간: 1 months following end of treatment
|
Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC) |
1 months following end of treatment
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
기간: 1 and 4 months following end of treatment
|
Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
기간: 1 and 4 months following end of treatment
|
Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response by the Revised INRC criteria at 4 months after the completion of therapy
기간: 4 months following end of treatment
|
Response by the Revised INRC criteria |
4 months following end of treatment
|
|
Progression-free survival
기간: Time from registration to progression or death, up to 5 years following end of treatment
|
Time to progress or death, whichever occurs first |
Time from registration to progression or death, up to 5 years following end of treatment
|
|
Overall survival - up to 5 years after End of Treatment
기간: Time from registration to the the date of death, up to 5 years following end of treatment
|
Overall survival |
Time from registration to the the date of death, up to 5 years following end of treatment
|
|
Hematological and renal toxicity according to CTCAE 5.0
기간: From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Hematological and renal toxicity according to CTCAE 5.0 |
From first treatment dose until the date of first documented progression, assessed up to 60 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
기간: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
Measured by SPECT/CT |
At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
기간: Throughout the trial treatment phase (5 years)
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology |
Throughout the trial treatment phase (5 years)
|
|
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
기간: At end of treatment, and 1 and 4 months after end of treatment.
|
Measured by SUVmax (maximum standardized uptake value) |
At end of treatment, and 1 and 4 months after end of treatment.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 의자: Jakob Stenman, MD PhD, Karolinska University Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- LuDO-N
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .